Health Funding Opportunities

blog navigation

Health Funding Opportunities

This is a collection of select grant funding opportunities available in the health sciences. This information is collected from a variety of sources including the Office for the Vice Chancellor for Research, Foundation Relations, and the Office for Proposal Development.

blog posts

  • Hirshberg Foundation 2017 Seed Grant Program

    The Hirshberg Foundation for Pancreatic Cancer Research Seed Grant program has been extremely successful in providing research support to basic and clinical scientists and investigators in the United States and overseas. To date the foundation has provided over $6 million for this program. The goals of the program are to: provide start-up funding for basic scientists and clinicians who intend to test innovative ideas for improving diagnosis and to develop new treatment modalities for pancreatic cancer; obtain preliminary data required for additional funding from other agencies for pancreatic cancer research; impact on the understanding of pancreatic cancer cell biology, biochemistry, physiology, morphology and response to therapy; and establish collaborations within the field for mutual projects that can be considered for further funding. 

    Eligibility and expectations: Doctor of Medicine (M.D.) or Doctor of Philosophy (Ph.D.) degree. Academic institutions of the U.S. and their investigators with the intent of developing a strong curriculum in pancreatic cancer research. All levels of academic faculty (assistant, associate and full professors). Research scientists and research associates with recommendations from their academic faculty supervisor(s). Postdoctoral fellows and young investigators after two years of completed training in pancreatic cancer research in any academic or private institution of the U.S. The Foundation expects that seed grant awards will generate quality abstracts, papers, presentations, as well as new proposals. The Foundation seeks and supports investigators whose primary intent is to build a strong curriculum in pancreatic cancer research.

    Amount: Up to $40,000 per year

    Deadline: August 15, 2017


  • Alzheimer's Disease Research Program Awards

    The Bright Focus Foundation (BFF) seeks applications for the following Alzheimer's Disease Research Program Awards:

    - Postdoctoral Fellowship Awards

    Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards fund projects in an established laboratory that will serve as the basis for the applicant's own independent research career. Postdoctoral Fellowships are available to junior and senior postdoctoral fellows. Applicants with pending appointments are eligible to apply, but the appointment must be finalized by the start of the award. The proposal should be initiated by the postdoctoral fellow and not the supervisor.

    Amount: $150,000

    - Standard Awards

    The standard award provides significant funding for researchers who have already generated some amount of preliminary data, but are often required to demonstrate additional, significant progress before they can apply to governmental or industrial funding agencies. The Principal Investigator (PI) position on BrightFocus Standard Awards are open to tenure- and non-tenure track investigators of any career stage who are appropriately trained to lead an independent research study, and are permitted by their organizations to manage grants and supervise key personnel.

    Amount: $300,000

    Deadline (for both award types): October 18, 2017


  • Pediatric Epilepsy Research Foundation (PERF) Grant for Infrastructure/Registry Research

    The Pediatric Epilepsy Research Foundation (PERF) seeks applications for the "PERF Grant for Infrastructure/Registry Research," a competitive grant in child neurology is directed at developing new infrastructure (i.e., registries and networks) or an existing infrastructure to advance the science of the research project. PERF will consider projects in all areas of child neurology, though research projects that promote advances in pediatric epliepsy and provide opportunities for training and/or mentoring young investigators are of particular interest. To be eligible for this grant, the applicant should be a child neurologist at any stage in his or her career and must be a legal resident of the United States or Canada.

    Amount: $200,000

    Pre-proposal Deadline: November 30, 2017

    Application Deadline: March 12, 2018


  • Klingenstein-Simons Fellowship Awards in the Neurosciences

    The Klingenstein-Simons Fellowship Awards in Neuroscience support, in the early stages of their careers, young investigators engaged in basic or clinical research that may lead to a better understanding of neurological and psychiatric disorders. The Klingenstein Fund and the Simons Foundation recognize that to accomplish this goal it is necessary to encourage a variety of new approaches.

    To qualify for an award investigators must hold the Ph.D. and/or M.D. degrees, and have completed all research training, including post-doctoral training. The candidate must be an independent investigator, within 4 years of receiving his/her first tenure track appointment at a university or medical institution. U.S. citizenship is not a requirement, but it is expected that candidates will be permanent residents of the U.S. and that their research will be carried out in U.S. institutions.

    Amount: $225,000

    Deadline: February 15, 2018


  • Michael J. Fox Foundation (MJFF) Awards

    The Michael J. Fox Foundation for Parkinson's Research (MJFF) seeks applications for the following awards:

    - Mitochondrial Biomarkers for Parkinson's Disease RFP

    - The Edmond J. Safra Fellowship in Movement Disorders RFP

    - Therapeutic Pipeline Program RFP

    - Target Advancement Program RFP

    For more information about these awards, please click here.

  • Chemical Probes for Novel Brain Targets (R01, R21)

    These FOAs intend to support investigators who have interest and capability to join efforts for the discovery of in vivo (R01) or cell-based (R21) chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (“validated hits”) for chemical optimization and bioassays for testing new analog compounds. Through these FOAs, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NEI, NIAAA, NIDA, NIA and/or NIDCD and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

    - Discovery of in vivo Chemical Probes for Novel Brain Targets (R01) RFP

    - Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21) RFP

    For more information about these awards, please click here.

  • Gates Foundation Novel Artemisinin Manufacturing Technologies Program

    The Bill & Melinda Gates Foundation has issued a Request of Proposals for its Novel Artemisinin Manufacturing Technologies program. The goal of the project is to develop novel approaches through the proof-of-concept stage for the manufacture of artemisinin and/or its precursors as a starting material or intermediate for the preparation of artemisinin-based active pharmaceutical ingredients. These approaches should demonstrate the potential — with a high probability of success — to meet aggressive cost targets when introduced at commercial scale.

    The focus of the RFP is on early research and lab-scale proof-of-concept testing of novel technologies. Awards will be made in three target areas, including artemisinin precursor (i.e., AA) production, chemical conversion of AA to artemisinin, and the direct production of artemisinin. The total value of all awards combined is estimated at $4.5 million, with individual awards not to exceed $1 million each for programs of up to twelve months. As the foundation recognizes that many interested parties may not have all the requisite capabilities in-house, proposers are highly encouraged to collaborate with partners, if needed. It is anticipated (but not guaranteed) that successful awardees will be requested to submit a proposal for additional development work, scale-up to pilot scale, generation of the necessary materials (e.g., cell banks), and technology transfer packages to enable manufacturing at multiple existing manufacturing facilities. To be eligible, applicants must be open to collaboration; be committed to providing global access to the technologies developed for the ultimate manufacturing of artemisinin; and be in good financial health. There are two deadlines to accommodate 1) potential rapid responses and awards for responders that can meet the tighter timelines (8/4/17); and 2) to allow for more time where it is required for partnering and/or the crafting of responses (9/29/17).

    Amount: Up to $1,000,000


    - Concept Memorandum submission due August 4, 2017

    - Concept Memorandum Template due September 29, 2017


  • ACA/MRA Cancer Related irAEs Research Program

    In recognition of the immense potential of checkpoint inhibition in combating multiple cancers and the reality that immune-related adverse events (irAEs) pose a challenge that, if addressed, could lead to better overall outcomes for patients and broader use, the American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) have partnered to support research leading to the reduction of irAEs and the improvement of overall outcomes for cancer patients treated with checkpoint immunotherapy. To that end, the two organizations have issued a Request for Applications for projects that test feasibility and generate preliminary data. MRA and ACS have each committed $1 million for the awards. The combined $2 million will be used to fund Multidisciplinary Team Awards and Pilot Awards.

    1) Multidisciplinary Team Awards: At least one grant of up to $1 million will be awarded in this category to foster interdisciplinary collaborative research and promote transformational advances with the potential for rapid clinical benefit. Letters of Intent must be received no later than August. Upon review, selected applicants will be invited to submit a full application by October 31, 2017.

    2) Pilot Awards: Up to five grants of up to $200,000 each will be awarded over two years to help seed the ground in this relatively young area of checkpoint irAE research. Applications must be received no later than October 16, 2017.

    Both categories are designed to support research on the prevention, early detection, reduction, and/or management of life-altering and/or outcome-limiting side-effects of checkpoint inhibitor therapy. Projects should focus on research leading to mitigation of irAEs while preserving or enhancing checkpoint blockade effectiveness. Research topics of interest include but are not limited to the biological basis and mechanism of irAEs; prevention of irAEs; detection and biomarkers; measurement of symptom clusters; and clinical translation of research.

    Amount: $200,000 for Pilot Awards: $1,000,000 for Multidisciplinary Team Award

    Deadline: October 16, 2017


  • ASCRS Career Development Grants

    The Research Foundation of the American Society of Colon and Rectal Surgeons (ASCRS) is accepting applications for its Career Development Grant program. The annual program provides young surgeons with the support necessary for the initiation and development of an academic career in colorectal surgery, with a focus on career development and mentorship of the individual rather than solely on the research proposal. Grants of up to $150,000 over two years will be awarded to academic investigators who demonstrate significant creativity in research relevant to the pathophysiology or management of diseases of the small bowel, colon, rectum, or anus.

    To be eligible, applicants must be within five years of their first full-time faculty appointment in a public or private nonprofit medical institution in the United States or Canada. Applicants also must be a citizen of the U.S. or Canada who has completed an approved colorectal surgery training program; if a foreign national, he or she must have a valid working visa at the time of application. All applicants must be an ASCRS member in good standing.

    Amount: Up to $150,000

    Deadline: October 1, 2017


  • Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites) (U24)

    The purpose of this FOA, issued by NINDS, is to invite currently awarded NeuroNEXT sites and potential new sites to participate as a Clinical Site in the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). This clinical research network develops and conducts multiple, scientifically sound, possibly biomarker-informed exploratory clinical trials evaluating the most promising therapies for neurological disorders, whether from academic, foundation or industry discoveries. Examples include Phase 2 clinical trials and clinical research studies aimed at validating biomarkers and clinical outcomes in preparation for clinical trials. The network provides a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. While the network is not specific to one disease, it has the capacity to coordinate a cadre of specialist investigators to implement studies efficiently in response to disease-specific opportunities. This FOA solicits applications for Clinical Sites. Separate FOAs solicit applications for the Clinical Coordinating Center and the Data Coordinating Center. The PD/PI must be a clinical trials expert with neurology trial expertise and a track record in successfully implementing clinical trials. 

    Amount: The maximum allowable direct cost per year for a NIH NeuroNEXT site will be $200,000

    Letter of Intent Deadline: New Date - August 26, 2017

    Application Deadline: New Date - September 26, 2017